 PHILADELPHIA, Oct. 28, 2020 GLOBE NEWSWIRE -- Passage Bio, Inc. NASDAQ: PASG, a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that the U.S. Food and Drug Administration FDA has granted Orphan Drug and Rare Pediatric Disease RPD designations to PBKR03 for the treatment of Krabbe disease Globoid Cell Leukodystrophy. Passage Bio expects to initiate a Phase 12 trial for PBKR03 in the first half of 2021. Krabbe disease is a rare and often life-threatening lysosomal storage disease that presents early in the patients life, resulting in progressive damage to both the brain and peripheral nervous system. 